CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model

Oncogene

Volumn 32, Issue 22, 2013, Pages 2726-2738

  Ward, Y ^a   Lake, R ^a   Martin, P L ^a   Killian, K ^a   Salerno, P ^a   Wang, T ^b   Meltzer, P ^a   Merino, M ^a   Cheng, S Y ^a   Santoro, M ^c   Garcia Rostan, G ^d   Kelly, K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

; vascular invasion; anaplastic; CD97; LPAR; metastasis; thyroid cancer

Indexed keywords

CD97 ANTIGEN; KI 67 ANTIGEN; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; THYROGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; CELL DEDIFFERENTIATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIUM; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH VESSEL METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; TUMOR CELL CULTURE; TUMOR INVASION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHATIDIC ACID; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

MUS MUSCULUS;

EID: 84879412193     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.301     Document Type: Article

References (33)

1. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
2. DeLellis R, Lloyd RV, Heitz P, Eng C. Pathology and genetics of tumors of endocrine organs. WHO classification of tumors. IARC: Lyonpress 2004.
3. Garcia-Rostan G, Sobrinho-Simoes M. Poorly differentiated thryoid carcinoma: an evolving entity. Diagn Histopathol 2011; 17: 114-123.
4. Wiseman SM, Loree TR, Rigual NR, Hicks Jr WL, Douglas WG, Anderson GR et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003; 25: 662-670.
5. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2011; 22: 395-404.
6. Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther 2011; 11: 387-402.
7. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011 2011 542358.
8. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A et al. CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 1996; 157: 5438-5447.
9. Yona S, Lin HH, Siu WO, Gordon S, Stacey M. Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci. 2008; 33: 491-500.
10. Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, Hamann J et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 2002; 118: 699-707.
11. Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 2005; 66: 1321-1326.
12. Mustafa T, Eckert A, Klonisch T, Kehlen A, Maurer P, Klintschar M et al. Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2005; 14: 108-119.
13. Steinert M, Wobus M, Boltze C, Schutz A, Wahlbuhl M, Hamann J et al. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 2002; 161: 1657-1667.
14. Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK et al. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. [Research Support, N.I.H., Intramural] 2011; 71: 7301-7311.
15. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7: 339-357.
16. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010; 91: 130-138.
17. Stortelers C, Kerkhoven R, Moolenaar WH. Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics 2008; 9: 387.
18. Jonkers J, Moolenaar WH. Mammary tumorigenesis through LPA receptor signaling. Cancer Cell 2009; 15: 457-459.
19. Meier CA, Parkison C, Chen A, Ashizawa K, Meier-Heusler SC, Muchmore P et al. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency. J Clin Invest 1993; 92: 1986-1993.
20. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA et al. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 2000; 97: 13209-13214.
21. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006; 30: 216-222.
22. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol 2011; 24(Suppl 2): S34-S43.
23. Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysopho-sphatidic acid receptor EDG2. Cancer Res. [Research Support, N.I.H., Intramural] 2007; 67: 11751-11759.
24. Guo R, Kasbohm EA, Arora P. Sample CJ, Baban B, Sud N, et al. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 2006; 147: 4883-4892.
25. Suzuki H, Willingham MC, Cheng SY. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002; 12: 963-969.
26. Ying H, Suzuki H, Furumoto H, Walker R, Meltzer P, Willingham MC et al. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis 2003; 24: 1467-1479.
27. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedenius J. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 2003; 13: 371-380.
28. Lu C, Zhu X, Willingham MC, Cheng SY. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene 2011; Sep: 12.
29. Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011; 30: 4307-4315.
30. Lin S, Wang D, Iyer S, Ghaleb AM, Shim H, Yang VW et al. The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 2009; 136: 1711-1720.
31. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009; 15: 539-550.
32. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J et al. Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 2004; 109: 833-838.
33. Gupte R, Patil R, Liu J, Wang Y, Lee SC, Fujiwara Y et al. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-meta-static activity. ChemMedChem 2011; 6: 922-935.